Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:55:40.015Z.
Calculation as of: 2026-10-06T22:55:40.015Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8f2565128bc52e6b8995a164e764e37a8d90e2a969ed0cbc93651ce94d5a839c
PE RATIO
N/A
Market Cap
$27.03M
PE Ratio
N/A
TTM Avg
1135.14
3Y Avg
1135.14
5Y Avg
1135.14
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| aTyr Pharma, Inc. (ATYR) | $27.79M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $28.08M | N/A | 20.42 | 20.42 | 20.42 |
| iTonic Holdings Ltd. (ITOC)vs › | $28.10M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $28.31M | N/A | 414.61 | 414.61 | 195.55 |
| BeyondSpring Inc. (BYSI)vs › | $28.47M | N/A | N/A | N/A | N/A |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $27.03M | N/A | 1135.14 | 1135.14 | 1135.14 |
| Quantum Cyber N.V. (QUCY)vs › | $29.37M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.57M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.74M | N/A | 0.40 | 0.40 | 0.40 |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $29.91M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.28
Forward EPS (Est.)
$-0.45
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
